Angiotensin II type 1 receptor antagonist (AIIRA) has been reported to improve exercise capacity and prognosis in patients with congestive heart failure (CHF). However, the effects of AIIRA on peripheral endothelium-dependent and -independent vasodilation remain undefined in this disorder. This study examined the effects and the mechanism of chronic AIIRA therapy on peripheral vasomotion in CHF. Twenty-six patients with CHF were recruited for this study. In protocol 1, 20 patients with CHF were randomly assigned into a losartan (AIIRA) group (n = 10) and a placebo group (n = 10). Forearm blood flow (FBF; ml/min per 100 ml tissue) changes induced by intra-arterial infusion of acetylcholine, sodium nitroprusside, and synthetic angiotensin II were determined by plethysmography before and 3 months after administration of a subdepressor dose of AIIRA or placebo. The goal of protocol 2 was to determine whether the effect of AIIRA is due to a nitric oxide-dependent mechanism in the remaining subset of the CHF group (n = 6). In this group, FBF responses to acetylcholine were examined with and without coadministration of a nitric oxide synthase inhibitor (N(G)-monomethyl->L-arginine; >L-NMMA) either before and 3 months after AIIRA therapy. No significant differences were found in changes in systemic blood pressure and basal FBF among patient groups during the study period. In protocol 1, although in both groups FBF responses induced by sodium nitroprusside as well as angiotensin II remained constant throughout the study, acetylcholine-induced FBF response was significantly enhanced in the losartan group (p < 0.05) but not in the placebo group. In protocol 2, acetylcholine-induced FBF response without >L-NMMA was significantly enhanced after AIIRA administration (p < 0.05), whereas this augmentation effect was diminished under >L-NMMA coinfusion. In conclusion, selective administration of an AIIRA for 3 months improves peripheral endothelium-dependent dilation in patients with CHF. This mechanism may be independent of direct AIIRA effects and may be due, in part, to increased bioavailability of nitric oxide.
Blood pressure (BP), renal arterial pressure and renal blood flow (RBF) were measured and blood samples were removed for determination of prostaglandin E (PGE) content in pentobarbital anesthetized dogs. Analysis of PGE with prior column separation was by radioimmunoassay utilizing a PGF antiserum and PGE specific anti-serum. The angiotensin antagonists 1-Sar-8-Ala-angiotensin II (saralasin) and 1-Sar-Ileu-angiotensin II (1-S-8-I A) were infused intraarterially to the kidney achieving concentrations of 20 and 50-60 ng/ml and 10 and 20 ng/ml, respectively before and during partial occlusion of the renal artery (RAO). 1-S-8-I A, 20 ng/ml, caused a small increase in renal vascular resistance (RVR) before RAO, but saralasin exerted no effect prior to RAO. Arterial and renal venous PGE levels were not affected by the antagonists. RAO caused a decrease in RVR and gradual increase in BP which ranged from 29-38% and 12-15 mmHg, respectively at the 20 min interval. The concentration of PGE in renal venous blood was found to be increased and the AV difference was significant when measurements were made using PGF antiserum, but no change was detectable when using PGE antiserum. The infusion of saralasin, but not 1-S-8-I A in the above concentrations caused a significant decrease in RVR during RAO; however, no changes in PGE levels were obtained with either agent. These results indicate that 1-S-8-I A has a more potent agonistic renal vasoconstrictor effect than saralasin as found before RAO, and saralasin exerts a renal vasodilator action only during RAO, which is due to angiotensin antagonism and not to PGE release.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.